Frequently Asked Questions About Sildenafil Hexal

An optional 16-week open-label extension phase for patients with active DU/reoccur-rence of DUs within 1 month of the end of the main treatment phase followed. Ultimately, treatment with riociguat did not reduce the number of digital ulcer burden compared to placebo at 16 weeks. The effects of statins on endothelial dysfunction and RP in SSc are currently under study by a group in Pittsburgh [69]. In this double-blind, randomized, placebo-controlled trial of atorvastatin 40 mg once daily vs placebo, 24 patients with early diffuse SSc (<3 years of SSc symptoms and RP) were enrolled if they had been on stable RP medications for at least 4 weeks. Improvement in microvascular endothelial function measured by reactive hyperemia index (RHI) was the primary outcome, and secondary outcomes included change in macrovascular endothelial function by brachial flow-mediated (FMD) dilation, and RP severity using the RP condition score (RCS) and visual analog scale (RP-VAS). In the atorvastatin treatment group, 60% (6/10) of patients improved their RHI, compared to 29% (4/14) in the placebo group (p = 0.12). No difference in change in peak FMD% was noted between groups.

Rights and permissions

The RCS decreased 2 points in the statin group compared to no change in the placebo (p = 0.12; Table 2). While the results demonstrated a non-significant improvement in microvascular endothelial function and RCS scores with the treatment of atorvastatin, the number of patients enrolled into the trial was small and thus it may have been underpowered to capture a significant difference between groups. Although acetylsalicylic acid (ASA) has been available for over 100 years, it has not been systematically studied in SSc, and it may potentially play a role in preventing SSc-related vascular injury. An ongoing study in Brazil aims to evaluate the effectiveness of ASA on microcirculation alterations in SSc patients.

In this phase 4 placebo-controlled clinical trial, 70 patients will be randomized to take either 100 mg daily ASA or placebo for 4 weeks. Outcome measures will include periungual panoramic capillary microscopy, videocapillaroscopy and laser Doppler imaging, as well as a panel of vascular biomarkers.

Copyright information

Investigators from National Jewish and the University of Pittsburgh are using pressure-volume loops to derive right ventriculo-vascular coupling, pulmonary impedance, and invasive cardiopulmonary exercise testing to compare the efficacy of chronic macitentan therapy in improving right ventricular hemodynamics, exercise capacity, and symptoms in scleroderma ILD-PH patients with and without PVL. As connective tissue disease-associated PAH has a relatively poor prognosis relative to PAH from other causes, recent trials have focused on identifying novel therapies to improve outcomes for such patients. The safety and efficacy of riociguat were recently evaluated in an exploratory analysis using the 12-week, phase III Pulmonary Arterial hypertension sGC-stimulator Trial (PATENT)-1, and the long-term extension PATENT-2 data. Investigators specifically examined the results of the study in the subset of patients enrolled who had PAH-associated with SSc or another defined connective tissue disease. In the prospectively planned analysis, it was determined that riociguat was well-tolerated and associated with positive trends in several endpoints, including 6-minute walk distance, and that these findings were sustained at 2 years in this patient subgroup, though further studies need to be done [82].

Active Substance

A similar approach was taken to examine the effects of selexipag using the GRIPHON study population, specifically looking at the subset of patients with PAH-associated connective tissue disease. This study is still recruiting and results are not yet available.

Possible side effects of TOURNES 100mg

Right ventricular failure has been associated with poor survival in SSc-PAH, and modest responses to existing therapies leave SSc patients with PAH with a higher relative mortality compared to PAH from other causes [72,73]. Monotherapy with prostacyclins, phosphodiesterase inhibitors, and endothelin receptor antagonists were the standard of care for many years. However, given the significant morbidity and mortality still associated with SSc-PAH, ongoing studies are now exploring alternative strategies, including the novel approach of combining these therapies (Table 5). [74] In addition, because approximately 50–70% of the pulmonary vasculature needs to be affected or obstructed before resting mPAP is elevated, investigators are also now exploring the treatment of exercise pulmonary hypertension (abnormal hemodynamic response to exercise), which is likely a marker of early pulmonary vascular disease. Determining whether the initiation of therapy at this earlier stage of PAH is beneficial for patients is another key focus of ongoing investigation [74].

Download citation

Data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry suggest that patients with SSc-related PAH have a significantly shorter time to clinical worsening when treated with phosphodiesterase-5 inhibitor (PDE5i) monotherapy compared to patients treated with endothelin receptor antagonists (ERA) and PDE5i combination therapy [75]. Such data have fueled interest in the study of combination therapy for PAH in SSc. Upfront combination therapy with phosphodiesterase inhibitors and endothelial receptor antagonists was recently studied in the a treatment-naïve group of patients with SSc-PAH. In this multi-center, open-label, clinical trial, patients were treated for 36 weeks with tadalafil 20 mg daily and ambrisentan 5 mg daily, with medication up-titration occurring at week 4 as tolerated. Investigators then compared the change in RV mass on cardiac MRI (standard volumetric cine images) from baseline to 36-week follow-up within subjects.

2.4. Pulmonary hypertension

They found that measures of right and left ventricular systolic and diastolic function were improved after treatment. In addition, combination therapy was associated with significant improvements in RV and LV function as measured by cardiac MRI [76], suggesting that combining these medications is a promising sildenafil generic therapeutic strategy. Although trials comparing the efficacy of combination therapy vs. monotherapy for pulmonary hypertension in SSc are limited, one study compared the efficacy and safety of monotherapy with phosphodiesterase inhibitors (sildenafil) versus initial combination therapy with phosphodiesterase inhibitors and endothelial receptor antagonists (sildenafil and bosentan) for treatment of SSc-PAH. In this single-center, double-blind, RCT, 34 patients with SSc-PAH (Pulmonary Artery Systolic Pressures >35 mmHg by echocar-diography), with a forced vital capacity >60% were randomized to receive either sildenafil plus placebo or to combination therapy with sildenafil plus bosentan for 24 weeks. Pulmonary arterial hypertension (PAH) affects approximately 7–12% of patients with SSc, and it is recognized as a leading cause of SSc-related death [70,71]. Right ventricular failure has been associated with poor survival in SSc-PAH, and modest responses to existing therapies leave SSc patients with PAH with a higher relative mortality compared to PAH from other causes [72,73]. Monotherapy with prostacyclins, phosphodiesterase inhibitors, and endothelin receptor antagonists were the standard of care for many years. However, given the significant morbidity and mortality still associated with SSc-PAH, ongoing studies are now exploring alternative strategies, including the novel approach of combining these therapies (Table 5).

• Do not drive or operate machinery after taking Sildenafil.
• It may cause temporary vision disturbances.
• Notify your doctor of any heart problems.
• Take the medication with water, not with a heavy meal.
• Keep out of reach of children.

[74] In addition, because approximately 50–70% of the pulmonary vasculature needs to be affected or obstructed before resting mPAP is elevated, investigators are also now exploring the treatment of exercise pulmonary hypertension (abnormal hemodynamic response to exercise), which is likely a marker of early pulmonary vascular disease. Determining whether the initiation of therapy at this earlier stage of PAH is beneficial for patients is another key focus of ongoing investigation [74].

Data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry suggest that patients with SSc-related PAH have a significantly shorter time to clinical worsening when treated with phosphodiesterase-5 inhibitor (PDE5i) monotherapy compared to patients treated with endothelin receptor antagonists (ERA) and PDE5i combination therapy [75].

Such data have fueled interest in the study of combination therapy for PAH in SSc. Upfront combination therapy with phosphodiesterase inhibitors and endothelial receptor antagonists was recently studied in the a treatment-naïve group of patients with SSc-PAH. In this multi-center, open-label, clinical trial, patients were treated for 36 weeks with tadalafil 20 mg daily and ambrisentan 5 mg daily, with medication up-titration occurring at week 4 as tolerated.

• Men with anatomical penile deformities should consult a doctor first.
• Keep a record of any side effects experienced.
• Medical review is recommended if no improvement occurs.
• Use with caution if you have heart disease.
• Be aware of potential drug interactions.

Investigators then compared the change in RV mass on cardiac MRI (standard volumetric cine images) from baseline to 36-week follow-up within subjects. They found that measures of right and left ventricular systolic and diastolic function were improved after treatment.

• Regular check-ups may be needed during prolonged use.
• Use with caution if you have low blood pressure.
• Sildenafil 100mg Hexal may cause you to feel dizzy.
• Avoid abrupt discontinuation without consulting a doctor.
• Keep medication in its original container to prevent misuse.

In addition, combination therapy was associated with significant improvements in RV and LV function as measured by cardiac MRI [76], suggesting that combining these medications is a promising sildenafil generic therapeutic strategy. Although trials comparing the efficacy of combination therapy vs. monotherapy for pulmonary hypertension in SSc are limited, one study compared the efficacy and safety of monotherapy with phosphodiesterase inhibitors (sildenafil) versus initial combination therapy with phosphodiesterase inhibitors and endothelial receptor antagonists (sildenafil and bosentan) for treatment of SSc-PAH. In this single-center, double-blind, RCT, 34 patients with SSc-PAH (Pulmonary Artery Systolic Pressures >35 mmHg by echocar-diography), with a forced vital capacity >60% were randomized to receive either sildenafil plus placebo or to combination therapy with sildenafil plus bosentan for 24 weeks. Ultimately, there were no significant changes between groups in pulmonary artery pressures at 24 weeks from baseline, or in secondary end points including change in 6 Minute Walk Distance or Time To Clinical Worsening (TTCW is defined as the first occurrence of all-cause deaths, PAH related hospitalization, worsening of symptoms defined as a decrease of >15% in 6 min walk distance and worsening of NYHA functional class); however, the investigators recommended larger, better powered studies, as combination therapy was well-tolerated in these patients [77] (NCT03053739). Because of the interest in treating early PAH, investigators have also explored the role of treating exercise-induced pulmonary hypertension (PH) in SSc. In cardiology, stress tests are increasingly utilized to better characterize hemodynamic changes, and a strong rationale now exists to suggest that a reduction in pulmonary vascular reserve may be an early signal of subclinical pulmonary hypertension [78]. Some studies now suggest that among SSc patients with normal resting mPAP, an excessive increase in mPAP during exercise coupled with an impairment in vascular dispensability may be indicative of an early stage of pulmonary vasculopathy, associated with reduced survival similar to patients with PH measured at rest [79,80]. A pilot study recently evaluated whether treatment of exercise-induced PH open-label daily ambrisentan positively affects changes in a 24-week interval in hemodynamics and exercise capacity in patients with SSc. Exercise-induced PH was defined as a mean pulmonary artery pressure of >30 mm Hg with maximum exercise and a transpulmonary gradient (TPG) of >15 mm Hg. Patients had normal hemodynamics at rest and were treated with 5–10 mg of ambrisentan daily.

Anwendungsbeschränkungen und Nebenwirkungen

An optional 16-week open-label extension phase for patients with active DU/reoccur-rence of DUs within 1 month of the end of the main treatment phase followed. Ultimately, treatment with riociguat did not reduce the number of digital ulcer burden compared to placebo at 16 weeks. The effects of statins on endothelial dysfunction and RP in SSc are currently under study by a group in Pittsburgh [69]. In this double-blind, randomized, placebo-controlled trial of atorvastatin 40 mg once daily vs placebo, 24 patients with early diffuse SSc (<3 years of SSc symptoms and RP) were enrolled if they had been on stable RP medications for at least 4 weeks. Improvement in microvascular endothelial function measured by reactive hyperemia index (RHI) was the primary outcome, and secondary outcomes included change in macrovascular endothelial function by brachial flow-mediated (FMD) dilation, and RP severity using the RP condition score (RCS) and visual analog scale (RP-VAS).

Authors and Affiliations

In the atorvastatin treatment group, 60% (6/10) of patients improved their RHI, compared to 29% (4/14) in the placebo group (p = 0.12). No difference in change in peak FMD% was noted between groups. The RCS decreased 2 points in the statin group compared to no change in the placebo (p = 0.12; Table 2). While the results demonstrated a non-significant improvement in microvascular endothelial function and RCS scores with the treatment of atorvastatin, the number of patients enrolled into the trial was small and thus it may have been underpowered to capture a significant difference between groups. Although acetylsalicylic acid (ASA) has been available for over 100 years, it has not been systematically studied in SSc, and it may potentially play a role in preventing SSc-related vascular injury.

2.1. Cutaneous sclerosis

An ongoing study in Brazil aims to evaluate the effectiveness of ASA on microcirculation alterations in SSc patients. In this phase 4 placebo-controlled clinical trial, 70 patients will be randomized to take either 100 mg daily ASA or placebo for 4 weeks. Outcome measures will include periungual panoramic capillary microscopy, videocapillaroscopy and laser Doppler imaging, as well as a panel of vascular biomarkers. This study is still recruiting and results are not yet available. Pulmonary arterial hypertension (PAH) affects approximately 7–12% of patients with SSc, and it is recognized as a leading cause of SSc-related death [70,71]. From baseline to 24 weeks, significant changes were identified in mean exercise pulmonary vascular resistance, mean 6 minute walk distance, mean exercise cardiac output, mean pulmonary artery pressure, and total pulmonary resistance.

About this chapter

Placebo-controlled studies are now needed to confirm that these findings are attributable to a drug effect and to define the optimal therapeutic regimen for these patients [81]. The application of statin therapy is novel in the management of PAH. Statins have a vasoprotective effect, and may therefore add value to the management of PAH, a condition in which vascular dysfunction is prominent. The effects of rosuvastatin on ameliorating vascular dysfunction in SSc-related pulmonary hypertension were recently examined in a study of 40 patients with SSc randomized to receive either rosuvastatin or placebo. All participants completed transthoracic echocardiography, 6 minute walk tests, were categorized by WHO functional class, and had tolerability and safety monitored.

The results of this phase-3 trial are not yet reported (NCT00984932). A new study is now seeking to understand patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) and how they fit into the treatment schema in SSc. Investigators from National Jewish and the University of Pittsburgh are using pressure-volume loops to derive right ventriculo-vascular coupling, pulmonary impedance, and invasive cardiopulmonary exercise testing to compare the efficacy of chronic macitentan therapy in improving right ventricular hemodynamics, exercise capacity, and symptoms in scleroderma ILD-PH patients with and without PVL. As connective tissue disease-associated PAH has a relatively poor prognosis relative to PAH from other causes, recent trials have focused on identifying novel therapies to improve outcomes for such patients. The safety and efficacy of riociguat were recently evaluated in an exploratory analysis using the 12-week, phase III Pulmonary Arterial hypertension sGC-stimulator Trial (PATENT)-1, and the long-term extension PATENT-2 data. Investigators specifically examined the results of the study in the subset of patients enrolled who had PAH-associated with SSc or another defined connective tissue disease. In the prospectively planned analysis, it was determined that riociguat was well-tolerated and associated with positive trends in several endpoints, including 6-minute walk distance, and that these findings were sustained at 2 years in this patient subgroup, though further studies need to be done [82]. A similar approach was taken to examine the effects of selexipag using the GRIPHON study population, specifically looking at the subset of patients with PAH-associated connective tissue disease.

3. Conclusion

Ultimately, there were no significant changes between groups in pulmonary artery pressures at 24 weeks from baseline, or in secondary end points including change in 6 Minute Walk Distance or Time To Clinical Worsening (TTCW is defined as the first occurrence of all-cause deaths, PAH related hospitalization, worsening of symptoms defined as a decrease of >15% in 6 min walk distance and worsening of NYHA functional class); however, the investigators recommended larger, better powered studies, as combination therapy was well-tolerated in these patients [77] (NCT03053739). Because of the interest in treating early PAH, investigators have also explored the role of treating exercise-induced pulmonary hypertension (PH) in SSc. In cardiology, stress tests are increasingly utilized to better characterize hemodynamic changes, and a strong rationale now exists to suggest that a reduction in pulmonary vascular reserve may be an early signal of subclinical pulmonary hypertension [78]. Some studies now suggest that among SSc patients with normal resting mPAP, an excessive increase in mPAP during exercise coupled with an impairment in vascular dispensability may be indicative of an early stage of pulmonary vasculopathy, associated with reduced survival similar to patients with PH measured at rest [79,80]. A pilot study recently evaluated whether treatment of exercise-induced PH open-label daily ambrisentan positively affects changes in a 24-week interval in hemodynamics and exercise capacity in patients with SSc.

Off-Label und potentielle Anwendungsgebiete

Exercise-induced PH was defined as a mean pulmonary artery pressure of >30 mm Hg with maximum exercise and a transpulmonary gradient (TPG) of >15 mm Hg. Patients had normal hemodynamics at rest and were treated with 5–10 mg of ambrisentan daily. From baseline to 24 weeks, significant changes were identified in mean exercise pulmonary vascular resistance, mean 6 minute walk distance, mean exercise cardiac output, mean pulmonary artery pressure, and total pulmonary resistance. Placebo-controlled studies are now needed to confirm that these findings are attributable to a drug effect and to define the optimal therapeutic regimen for these patients [81]. The application of statin therapy is novel in the management of PAH.

Idiopathische pulmonal-arterielle Hypertonie

Statins have a vasoprotective effect, and may therefore add value to the management of PAH, a condition in which vascular dysfunction is prominent. The effects of rosuvastatin on ameliorating vascular dysfunction in SSc-related pulmonary hypertension were recently examined in a study of 40 patients with SSc randomized to receive either rosuvastatin or placebo. All participants completed transthoracic echocardiography, 6 minute walk tests, were categorized by WHO functional class, and had tolerability and safety monitored. The results of this phase-3 trial are not yet reported (NCT00984932). A new study is now seeking to understand patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) and how they fit into the treatment schema in SSc.